Method development and Validation of UV Spectrophotometric estimation of Remogliflozin Etabonate in bulk and its tablet dosage form-Reference-Cited by-同舟云学术

Method development and Validation of UV Spectrophotometric estimation of Remogliflozin Etabonate in bulk and its tablet dosage form

Published:2021-04-29 Issue: Volume: Page:2042-2044
ISSN:0974-360X
Container-title:Research Journal of Pharmacy and Technology
language:en
Short-container-title:RJPT

Author:

Vidhi Dave¹,Patel Paresh¹

Affiliation:

1. Department of Quality Assurance, S.K. Patel College of Pharmaceutical Education and Research, Ganpat University, Kherva , Gujarat, India

Abstract

A simple, precise and sensitive UV spectrophotometric method has been developed for the estimation of Remogliflozin etabonate in bulk and pharmaceutical dosage Form. Remogliflozin etabonate shows Maximum Absorbance at 229nm. Beer’s law was obeyed in range of 2-10µg/ml. The correlation coefficient was found to be 0.9990. The result of interday and intraday precision shows standard deviation ranging from 0.050% - 0.254% and 0.058% - 0.258% for three concentration and three replicates. The Percentage recovery was found to be in the range of 98.94% - 99.86%. The LOD and LOQ were found to be 0.037µg/ml and 0.113µg/ml respectively. The purposed method was novel and successfully applied for the determination of Remogliflozin Etabonate in Tablet Dosage Form. The method was successfully validated according to ICH guidelines.

Publisher

A and V Publications

Subject

Pharmacology (medical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Reference18 articles.

1. https://www.drugbank.ca/drugs/DB12935, accessed on August 2019.

2. https://pubchem.ncbi.nlm.nih.gov/compound/9871420, accessed on August 2019.

3. Kapur A, Robin O’Connor-Semmes. First human dose-escalation study with Remogliflozin etabonate elaborate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. BMC Pharmacology and Toxicology, 2013, 14(26).

4. Beckett A H., and Stenlake J B. Practical Pharmaceutical Chemistry. part-ii, 4th Edn; CBS publishers and distributors. India, 1997. 281.

5. Davidson A G., Ultra-visible absorption Spectrophotometry. Practical Pharmaceutical chemistry. 4th Edn, part-ii, CBS publisher and distributors, 1997, 275-337

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stability Indicating RP-HPLC Method Development and Validation for Simultaneous Estimation of Metformin Hydrochloride and Remogliflozin Etabonate in Bulk and Tablet Formulation;Research Journal of Pharmacy and Technology;2024-05-15

2. Development and Validation of UV Spectrophotometric Method for Simultaneous Estimation of some SGLT-2 and DPP-4 inhibitor in Bulk and Pharmaceutical Dosage Form;Research Journal of Pharmacy and Technology;2024-04-22

3. Remogliflozin Etabonate (Re) the Latest Addition to the SGLT2 Inhibitor;Asian Journal of Pharmacy and Technology;2024-03-04

4. A green reversed phase HPLC and HPTLC methods and their validation for simultaneous estimation of remogliflozin, vildgliptin and metformin in fixed dose combination formulation;Journal of Liquid Chromatography & Related Technologies;2023-12-03

5. Development and Validation of Analytical Method by Reverse Phase HPLC for the Estimation of Escitalopram oxalate in Bulk and Dosage form;Research Journal of Pharmacy and Technology;2023-10-31